Abstract
Cervical lesions can be caused by pathogens, hormonal changes or by cervical injury. The recommended treatment in all cases is excision. Local re-epithelialization therapy should be initiated preoperatively and postoperatively. The present study assessed the post-market performance and tolerability of Cerviron® ovules in the treatment and management of cervical lesions postoperatively. The study population included 345 participants aged 20-70 years with either a cervical lesion under treatment or with recent surgical removal of a cervical lesion. The degree of re-epithelialization of the cervical mucosa was improved in 73.17% of the patients evaluated during routine colposcopy exams and 92.73% of patients recorded no bleeding. When adding Cerviron® either as monotherapy or in association with other antimicrobials in postoperative care of the cervical ectropion, improved postoperative outcomes such as reduced post-interventional bleeding and a superior quality of healing were observed. The study and its details are registered in www.clinicaltrials.gov under ID NCT05668806.
Competing Interest Statement
Ema Peta and Florentina Dimcevici Poesina are employed at Perfect Care Distribution SRL. Perfect Care Distribution SRL. Ramona Petrita and MDX Research, as CRO provided services in another similar study. All other authors declare no conflicts. The funder Perfect Care Distribution SRL had no role in the design of the study, or in the collection, analyses, or interpretation of data, or in the writing of the manuscript, or in the decision to publish the results.
Clinical Trial
NCT05668806
Funding Statement
Perfect Care Distribution SRL (https://www.perfectcare.ro/), the study sponsor, offered the tested medical devices and a partial grant support.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Comisia Nationala de Bioetica a Medicamentului si a Dispozitivelor Medicale (CNBMDM) waived the ethical approval for this work, according to the European Medical Device Regulation MDR 2017/745, concerning data collected in the post-marketing clinical follow-up plan for medical devices, Annex XIV, part B.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Order of authors and in abstract- elimination of the expression " stimulation of the granulation tissue"
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
